The die has been cast - Opdivo (nivolumab) will be re-priced before the next FY2018 drug price revision. Now the question is how much lower? When? And, how will it affect the price-setting of its archrival Keytruda (pembrolizumab)? Tug-of-War over…
To read the full story
Related Article
- Shiozaki Does Not Rule Out Price Cut of Over 25% for Opdivo
October 27, 2016
- Keytruda’s November Listing Skip Likely amid Opdivo Re-Pricing Fuss
October 24, 2016
COMMENTARY
- Rare Cancer Case Raises New Questions about AAV Gene Therapy Safety
July 27, 2026
- A Turning Point for Pharma? Chuikyo Reform Could Open Door to Greater Industry Role
July 13, 2026
- DORA Use Could Expand as Japan Opens Door to “Sleep Disorders” Specialty
July 6, 2026
- New Generic Listings Plunge, Industry Heads for a Shakeout
July 1, 2026
- Adaptation, Diversification Key as Drug Wholesalers Face Profit Squeeze
June 16, 2026
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…





